Eligibility for icosapent ethyl in a French population of coronary outpatients with type 2 diabetes.

Introduction: We determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD).

Methods: Consecutive patients with type 2 diabetes and CAD were prospectively included from 03/2019 to 12/2020.

Results: 574 patients were included; mean age 71 years, 81% males, with a high prevalence of other risk factors (81% hypertension).